23andMe Inc.

Company Overview

23andMe is a U.S.-based company established in 2006. The company operates through two primary segments in the direct-to-consumer genetic testing market (DTC GT): Consumer and Research Services and Therapeutics.

Consumer and Research Services: This segment features the Personal Genome Service (PGS), telehealth offerings, and research services. PGS delivers genetic reports on ancestral origins, health risks, carrier conditions, and how genetics can affect responses to medications. The company aims to provide customers with valuable genetic information that supports better health decisions and proactive health management.

Therapeutics: This segment is dedicated to using genetic insights to identify new drug targets and develop innovative therapies. It involves research and development in fields like oncology and inflammatory diseases. Revenue is generated from licensing intellectual property related to these drug targets.

Financial Highlights (FY 2024)

Company's Business Segments

• Consumer Services : Personal Genome Service, Telehealth Business, DNA Testing, Genetic Ancestral Origins Services.
• Research Services : Through Research Services, company use their vast Database of Genetic and Phenotypic information provided by consenting customers to discover insights into the Genetic Origins of disease and to identify and validate targets for Drug Development.